NasdaqCM:MEIP

Stock Analysis Report

Executive Summary

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • MEI Pharma has significant price volatility in the past 3 months.

Share Price & News

How has MEI Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.2%

NasdaqCM:MEIP

0.6%

US Biotechs

0.8%

US Market


1 Year Return

-56.3%

NasdaqCM:MEIP

-10.2%

US Biotechs

1.9%

US Market

MEIP underperformed the Biotechs industry which returned -9.7% over the past year.

MEIP underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

MEIPIndustryMarket
7 Day4.2%0.6%0.8%
30 Day13.1%-0.8%3.4%
90 Day-21.7%-0.5%2.1%
1 Year-56.3%-56.3%-9.4%-10.2%4.2%1.9%
3 Year13.7%13.7%6.0%2.4%46.7%37.2%
5 Year-71.2%-71.2%5.0%-0.09%62.3%44.5%

Price Volatility Vs. Market

How volatile is MEI Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MEI Pharma undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

MEI Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).

MEI Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

MEI Pharma is loss making, we can't compare its value to the US Biotechs industry average.

MEI Pharma is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for MEI Pharma, we can't assess if its growth is good value.


Price Based on Value of Assets

MEI Pharma is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is MEI Pharma expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

46.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

MEI Pharma's revenue is expected to grow significantly at over 20% yearly.

MEI Pharma's earnings are expected to grow significantly at over 20% yearly.

MEI Pharma's revenue growth is expected to exceed the United States of America market average.

MEI Pharma's earnings growth is expected to exceed the United States of America market average.

MEI Pharma's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if MEI Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has MEI Pharma performed over the past 5 years?

2.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

MEI Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare MEI Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare MEI Pharma's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if MEI Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if MEI Pharma has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if MEI Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is MEI Pharma's financial position?


Financial Position Analysis

MEI Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

MEI Pharma's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

MEI Pharma has no debt.

MEI Pharma has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

MEI Pharma has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

MEI Pharma has sufficient cash runway for 2.5 years based on current free cash flow.

MEI Pharma has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 57.2% each year.


Next Steps

Dividend

What is MEI Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate MEI Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate MEI Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as MEI Pharma has not reported any payouts.

Unable to verify if MEI Pharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as MEI Pharma has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of MEI Pharma's salary, the management and board of directors tenure and is there insider trading?

4.2yrs

Average management tenure


CEO

Dan Gold (65yo)

9.4yrs

Tenure

US$2,985,416

Compensation

Dr. Daniel P. Gold, also known as Dan, Ph.D. has been the Chief Executive Officer and President of MEI Pharma, Inc. (Alternate Name: Marshall Edwards Inc.), a subsidiary of Novogen Limited since April 26,  ...


CEO Compensation Analysis

Dan's remuneration is higher than average for companies of similar size in United States of America.

Dan's compensation has increased whilst company is loss making.


Management Age and Tenure

4.2yrs

Average Tenure

59.5yo

Average Age

The tenure for the MEI Pharma management team is about average.


Board Age and Tenure

6.3yrs

Average Tenure

66yo

Average Age

The tenure for the MEI Pharma board of directors is about average.


Insider Trading

More shares have been bought than sold by MEI Pharma individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$26,07509 Sep 19
Christine White
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares15,000
Max PriceUS$1.74

Ownership Breakdown


Management Team

  • Brian Drazba (58yo)

    Secretary & CFO

    • Tenure: 2.4yrs
    • Compensation: US$1.02m
  • Richard Ghalie (61yo)

    Senior Vice President of Clinical Development

    • Tenure: 3.5yrs
  • Dan Gold (65yo)

    CEO, President & Director

    • Tenure: 9.4yrs
    • Compensation: US$2.99m
  • David Urso (55yo)

    COO, Senior VP of Corporate Development & General Counsel

    • Tenure: 1.2yrs
    • Compensation: US$1.25m
  • David Walsey

    Vice President of IR & Corporate Communications

    • Tenure: 0yrs
  • Karen Potts (56yo)

    Senior Vice President of Regulatory Affairs

    • Tenure: 4.9yrs
  • Robert Mass (65yo)

    Chief Medical Officer

    • Tenure: 8.3yrs
    • Compensation: US$879.31k

Board Members

  • Tamar Howson (70yo)

    Non-Executive Director

    • Tenure: 0.2yrs
  • Fred Driscoll (68yo)

    Non-Executive Director

    • Tenure: 1.6yrs
    • Compensation: US$68.11k
  • Dan Gold (65yo)

    CEO, President & Director

    • Tenure: 9.4yrs
    • Compensation: US$2.99m
  • Bill Rueckert (66yo)

    Non Executive Director

    • Tenure: 8.4yrs
    • Compensation: US$148.91k
  • Nick Glover (50yo)

    Non-Executive Director

    • Tenure: 6.3yrs
    • Compensation: US$138.91k
  • Kevan Clemens (75yo)

    Non Executive Director

    • Tenure: 4.8yrs
    • Compensation: US$132.91k
  • Christine White (67yo)

    Non-Executive Chairman

    • Tenure: 3.8yrs
    • Compensation: US$157.03k
  • Tom Reynolds (60yo)

    Non-Executive Director

    • Tenure: 6.6yrs
    • Compensation: US$133.91k
  • Charles Baltic (58yo)

    Non-Executive Director

    • Tenure: 7.9yrs
    • Compensation: US$141.41k

Company Information

MEI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MEI Pharma, Inc.
  • Ticker: MEIP
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$146.534m
  • Shares outstanding: 73.63m
  • Website: https://www.meipharma.com

Number of Employees


Location

  • MEI Pharma, Inc.
  • 3611 Valley Centre Drive
  • Suite 500
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEIPNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2003
MMIADB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003
0JW9LSE (London Stock Exchange)YesCommon StockGBUSDDec 2003

Biography

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company’s clinical drug candidate includes Pracinostat, an oral avail ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:06
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.